Summary: A new primate study shows that a brain-selective estrogen prodrug can prevent many of the cognitive and physiological side effects caused by anti-estrogen breast cancer treatments. The compound, 10β,17β-dihydroxyestra-1,4-dien-3-one (DHED), is designed to raise estrogen levels only within the brain while leaving peripheral tissues — including breast tissue — free of added hormone exposure.
Using aged common marmosets as a translational model, researchers found that DHED increases cerebral estrogen, reverses neural changes caused by aromatase inhibition, and meaningfully improves memory performance and sleep stability. The work bridges earlier rodent data and represents an important step toward therapies that preserve the life-saving anti-cancer effects of aromatase inhibitors while protecting brain function and quality of life.
Key Facts
- Treatment adherence is threatened by side effects: Aromatase inhibitors such as letrozole reduce estrogen production systemically to limit recurrence of estrogen-receptor–positive breast cancer, but this systemic estrogen loss commonly produces severe cognitive and somatic symptoms that cause many patients to stop therapy.
- Targeted brain delivery: DHED is a brain-selective prodrug that is metabolized to 17β-estradiol (E2) inside the brain. By converting to active estrogen only in cerebral tissues, DHED aims to protect neural circuits without increasing estrogen in peripheral organs where it could promote tumor growth.
- Translation in non-human primates: The research team moved beyond rodent models to test DHED in aged marmosets, a primate species with brain and aging features that better approximate human menopause-related changes and cognitive aging.
- Rescue of neural function and behavior: In letrozole-treated marmosets, chronic DHED administration raised brain E2 levels, improved short-delay memory performance, reduced sleep fragmentation, and restored hippocampal neuronal membrane properties and excitability that were altered by aromatase inhibition.
- Sex differences in thermoregulation: DHED produced divergent effects on body temperature control in males versus females, an unexpected finding that highlights the need for dose optimization and sex-specific safety assessments in future studies.
- Potential beyond oncology: While developed to support breast cancer patients on aromatase inhibitors, DHED may also have broader relevance for alleviating menopausal cognitive and sleep complaints in the general population, pending further research.
Source: SfN
Background: Most hormone-receptor–positive breast cancers are driven by estrogens. Aromatase inhibitors such as letrozole lower systemic estrogen to reduce the risk of cancer recurrence, but the resulting deprivation of estrogen in the brain commonly causes memory deficits, insomnia, mood changes, and hot flashes. These side effects reduce quality of life and are a major cause of nonadherence to life-prolonging therapy.
Preclinical rodent studies previously showed that DHED selectively supplies estrogen to the brain without elevating peripheral estrogen levels. In the new study published in the Journal of Neuroscience, a research team led by Agnès Lacreuse at the University of Massachusetts Amherst assessed whether those findings translate to a primate model. They used aged common marmosets to model aspects of human menopause and cognitive aging more accurately than mouse models.
Marmosets treated with letrozole were given chronic oral DHED. The compound produced robust increases in brain E2 across multiple regions while leaving systemic estrogen unchanged. Functionally, DHED prevented letrozole-induced cognitive slowing, improved performance on a hippocampal-dependent memory task at short delays, reduced sleep fragmentation, and restored neuronal membrane potential and excitability in hippocampal neurons. However, the drug affected thermoregulation differently in males and females, prompting the researchers to plan additional dosing and mechanism studies.
Lead author Agnès Lacreuse commented that these results support DHED as a promising candidate to preserve brain health for breast cancer patients on aromatase inhibitors and possibly to address broader menopausal symptoms. The team intends to investigate the precise neural mechanisms by which DHED acts and to refine dosing to address the observed sex-specific thermoregulatory effects.
Key Questions Answered:
A: Because systemic estrogen depletion leads to severe side effects. Aromatase inhibitors block estrogen synthesis to protect against cancer recurrence, but that estrogen loss affects the brain and other systems, producing memory problems, sleep disruption, hot flashes, and other symptoms that often drive patients to discontinue treatment.
A: DHED is engineered as a brain-selective prodrug. It is converted to active 17β-estradiol only within cerebral tissues, restoring estrogen signaling in the brain while avoiding increases in peripheral estrogen concentrations that could stimulate tumor cells.
A: Aged marmosets have more complex brain anatomy and endocrine-aging patterns that better resemble human menopause and cognitive aging than rodent models. Demonstrating efficacy and brain-specific action in primates strengthens the translational case for further development toward clinical testing.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- The journal paper was reviewed in full by staff.
- Additional context was added by editorial staff for clarity.
About this neuropharmacology and cancer research news
Author: SfN Media
Source: SfN
Contact: SfN Media — SfN
Image: Image credited to Neuroscience News
Original Research: Open access. Brain-Selective Estrogen Therapy in Male and Female Marmosets Partially Counteracts the Adverse Effects of Aromatase Inhibition on the Brain and Behavior — Hannah Cournoyer et al., Journal of Neuroscience. DOI: 10.1523/JNEUROSCI.2021-25.2026
Abstract (concise summary):
Brain-Selective Estrogen Therapy in Male and Female Marmosets Partially Counteracts the Adverse Effects of Aromatase Inhibition on the Brain and Behavior
Aromatase inhibitors prevent estrogen synthesis and reduce breast cancer recurrence, but also produce cognitive deficits, sleep disruption, and thermoregulatory symptoms that reduce quality of life and contribute to nonadherence. DHED is a prodrug that selectively converts to 17β-estradiol (E2) within the brain in animal models, sparing peripheral tissues from estrogen exposure. In aged marmosets treated with the aromatase inhibitor letrozole, chronic oral DHED robustly increased brain E2 without raising peripheral estrogen, improved hippocampal-dependent memory and sleep fragmentation, and normalized neuronal membrane properties affected by aromatase inhibition. Sex-dependent effects on thermoregulation were observed and require further study. Overall, these results support continued development of DHED as a brain-specific hormonal therapy to improve cognitive and behavioral outcomes in patients receiving aromatase inhibitors and potentially in other menopausal conditions.